SoCalBio Company
Directory |
|
Browse the SoCalBio list of medtech/biotech/pharma/IVD
companies based in the six-county Greater Los Angeles region
Sponsored
by
|
Industry & Company
Headlines
|
- Comparative-Effectiveness Bill to Be
Introduced in the U.S. Senate
A bill establishing a
comparative-effectiveness research institute is scheduled for introduction
in the Senate this week. The Comparative Effectiveness Research Act of 2008,
sponsored by Sens. Kent Conrad (D-N.D.) and Max Baucus (D-Mont.), would
establish an institute to evaluate the effectiveness of different drugs and
medical devices that exist for the same treatment ... Read
more
- FDA to Take Key Step in
Stem Cell Research
FDA advisors met last Thursday and Friday to discuss
how embryonic stem cell clinical trials would be conducted ... Read
article at CNNMoney.com
- Need Defense? Think Medical
Supplies
Conventional wisdom says investing in health care is a smart way to defend
against tough economic times. These days, however, purchasers of many
defensive stocks, from major pharmaceuticals to large biotechs to big-name
device makers, are suffering from offensive returns. Still, there's an
island of cheer amid this medical malaise. When it comes to a good defense,
you can't beat catheters, syringes, needles, instruments and hospital
supplies .. Read
article at TheStreet.com.
- Drugmakers
Lead Pack in Spending on Lobbying in 2007
Among industries, the drugmakers, such as Amgen and Pfizer;
and health products companies, such as Johnson & Johnson and Boston
Scientific Corp., spent $227 million collectively last year ... Read
article at Yahoo Finance
- Amgen Develops Six Cancer Drugs as Anemia Sales Fall
Six new cancer drugs are in the works to help Amgen recuperate from slumping sales of Aranesp and Epogen, its blockbuster anemia treatments. Amgen is developing drugs to attack tumors using three approaches, including one that would provoke
apoptosis .... Reed
more at Bloomberg.com
- MannKind Being Its Own
"Man" About Inhalable Insulin
The company put out a press release saying
that in mice, animals and people it has seen no evidence yet of
carcinogenicity with its inhaled insulin device. But the company halted
talks about partners in the wake of the Pfizer announcement
about the cancer cases in Nektar's Exubera trials ... Rea
Mike Huckman's blog at CNBC
- Other Recent News:
|
Jobs Available
|
|
|
|
|
